研究者詳細 - 田中　章仁

論文 - 田中　章仁

分割表示 >> ／全件表示 77 件中 1 - 77 件目

Urinary presepsin can efficiently detect T-cell-mediated rejection in patients who have undergone kidney transplantation 査読有り Open Access

Tomohiro Kawazoe, Akihito Tanaka, et al.

Clinical and Experimental Nephrology 2025年4月

Ameliorative Effect of an Anti-microRNA-21 Oligonucleotide on Animal and Human Models of Cystic Kidney Disease 査読有り Open Access

Yuhei Noda, Noritoshi Kato, Fuminori Sato, Yuji Suzuki, Shoma Tsubota, Hiroki Kitai, Shintaro Komatsu, Akihito Tanaka, et al.

Kidney360 2025年4月

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol 査読有り Open Access

Shinobu Shimizu, Akihito Tanaka, et al.

PLoS One 20 巻 ( 3 ) 頁： e0320070 - e0320070 2025年3月

Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study 査読有り

Keisuke Sunohara, Chikao Onogi, Akihito Tanaka, et al.

BMC Nephrology 25 巻 ( 442 ) 頁： 1 - 10 2024年12月

Urinary presepsin is a novel biomarker capable of directly assessing monocyte/macrophage infiltration in kidney diseases 査読有り

Shunsuke Niwa, Akihito Tanaka, et al.

Scientific reports 14 巻 ( 30088 ) 頁： 1 - 12 2024年12月

MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during treatment of plaque psoriasis with bimekizumab 査読有り

Takuya Sugiura, Tomohito Doke, Akihito Tanaka, et al.

CEN Case Reports 2024年9月

Safety and Tolerability of ADR-001 Therapy for Immunoglobulin A Nephropathy 査読有り

Tanaka A, et al.

Kidney360 2024年8月

Detecting and exploring kidney-derived extracellular vesicles in plasma 査読有り

Shintaro Komatsu, Noritoshi Kato, Hiroki Kitai, Yoshio Funahashi, Yuhei Noda, Shoma Tsubota, Akihito Tanaka, et al.

Clinical and Experimental Nephrology 28 巻 ( 7 ) 頁： 617 - 628 2024年7月

Prognosis of microscopic polyangiitis is well predictable in the first 2 weeks of treatment 査読有り

Akiko Owaki, Akihito Tanaka, et al.

Clinical and Experimental Nephrology 28 巻頁： 701 - 706 2024年7月

A case of non-traumatic rectus sheath hematoma in a post-kidney transplant patient undergoing catheter embolization during anticoagulation treatment for atrial fibrillation 査読有り

Kumiko Fujieda, Shoji Saito, Akihito Tanaka, et al.

CEN Case Reports 2024年5月

Clinical impact of proteinuria and hematuria remission criteria in IgA nephropathy patients defined by the Japanese Society of Nephrology 査読有り

NEPHROLOGY DIALYSIS TRANSPLANTATION 39 巻頁： I736 - I737 2024年5月

Safety and Tolerability of adipose-derived mesenchymal stem cell "ADR-001" in the treatment of immunoglobulin A nephropathy 査読有り

NEPHROLOGY DIALYSIS TRANSPLANTATION 39 巻頁： I740 - I740 2024年5月

Establishment of an adverse effect prevention protocol on plasma exchange using fresh frozen plasma prior to ABO-incompatible living donor kidney transplantation at our hospital 査読有り

Akihito Tanaka, et al.

Therapeutic Apheresis and Dialysis ( 1 ) 頁： 152 - 157 2024年2月

Changes in antibody titer after four and five doses of the SARS-CoV-2 vaccine in Japanese post-kidney transplant patients 査読有り

Kumiko Fujieda, Akihito Tanaka, et al.

Ther Apher Dial 2024年2月

Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium/calcium polystyrene sulfonate 査読有り

Chikao Onogi, Yu Watanabe, Akihito Tanaka , et al.

Clin Kidney J 17 巻 ( 2 ) 頁： sfae021 2024年2月

A case of late-onset organizing pneumonia following COVID-19 infection in a post-kidney transplant patient 査読有り

Kumiko Fujieda, Shoji Saito, Akihito Tanaka, et al.

CEN Case Rep 2024年2月

Caroli病(先天性多発肝内胆管拡張症)による難治性胆管炎,末期腎不全症例に肝腎同時移植を実施した1例査読有り

佐野優太, 石田昇平, 佐野友康, 加藤真史, 田中章仁ら

日本臨床腎移植学会雑誌 2023年12月

Mesenchymal stem/stromal cells generated from induced pluripotent stem cells are highly resistant to senescence 査読有り

Tomonori Aoi, Akihito Tanaka, et al.

Nagoya J Med Sci 2023年11月

Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis 査読有り

Akihito Tanaka, et al.

Sci Rep ( 13(1) ) 頁： 16051 2023年9月

Current status of low-density lipoprotein apheresis treatment for patients with peripheral artery disease and chronic kidney disease in Japanese clinical database 査読有り

Yu Watanabe, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama

Therapeutic Apheresis and Dialysis 2023年8月

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits and atypical pathological findings treated with corticosteroid and rituximab 査読有り

Machi Mori, Akihito Tanaka, Kayaho Maeda, Shoji Saito, Kazuhiro Furuhashi, Shoichi Maruyama

CEN Case Rep 2023年8月

Prognosis and incidence of infections in chronic kidney disease patients with membranous nephropathy enrolled in a large Japanese clinical claims database 査読有り

Takuro Matsuzaki, Yu Watanabe, Akihito Tanaka, Kazuhiro Furuhashi, Shoji Saito, Shoichi Maruyama

BMC Nephrology 24 巻 ( 1 ) 頁： 126 2023年5月

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients 査読有り

Kumiko Fujieda, Akihito Tanaka , et al.

Vaccines (Basel) 11 巻 ( 1 ) 頁： 134 2023年1月

Influence of COVID-19 on the 10-year carbon footprint of the Nagoya University Hospital and medical research centre 査読有り

Hikaru Morooka, Takanori Yamamoto, Akihito Tanaka, Kazuhiro Furuhashi, Yasuhiro Miyagawa and Shoichi Maruyama

Globalization and Health 18 巻頁： 92 2022年11月

Mesenchymal stem cells exert renoprotection via extracellular vesicle-mediated modulation of M2 macrophages and spleen-kidney network 査読有り

Yuko Shimamura, Kazuhiro Furuhashi, Akihito Tanaka, et al.

Communication Biology 5 巻 ( 1 ) 頁： 753 2022年7月

Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy 査読有り

Tanaka Akihito, et al.

Frontiers in Medicine 9 巻頁： 883168 2022年5月

Antibody response to double SARS-CoV-2 mRNA vaccination in Japanese kidney transplant recipients 査読有り

Kumiko Fujieda, Akihito Tanaka, et al.

Scientific Reports 12 巻頁： 6850 2022年4月

Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease and Sleep Apnea Syndrome 査読有り

Yu Watanabe, Akihito Tanaka, et al.

Frontiers in Medicine 9 巻頁： 899359 2022年3月

Abnormal magnesium levels and their impact on death and acute kidney injury in critically ill children 査読有り

Morooka Hikaru, Tanaka Akihito, Kasugai Daisuke, Ozaki Masayuki, Numaguchi Atsushi, Maruyama Shoichi

PEDIATRIC NEPHROLOGY 2021年10月

記述言語：日本語出版者・発行元：Pediatric Nephrology

Background: The prevalence of magnesium imbalance in critically ill children is very high. However, its significance in the development of acute kidney injury (AKI) and mortality remains unknown. Methods: In this retrospective observational study from 2010 to 2018, the pediatric-specific intensive care database was analyzed. We included critically ill children aged > 3 months and those without chronic kidney disease. Patients were diagnosed with AKI, according to the Kidney Disease Improving Global Outcomes (KDIGO) study. We calculated the initial corrected magnesium levels (cMg) within 24 h and used a spline regression model to evaluate the cut-off values for cMg. We analyzed 28-day mortality and its association with AKI. The interaction between AKI and magnesium imbalance was evaluated. Results: The study included 3,669 children, of whom 105 died within 28 days, while 1,823 were diagnosed with AKI. The cut-off values for cMg were 0.72 and 0.94 mmol/L. Both hypermagnesemia and hypomagnesemia were associated with 28-day mortality (odds ratio [OR] = 2.99, 95% confidence interval [CI] = 1.89–4.71, p < 0.001; OR = 2.80, 95% CI = 1.60–4.89, p < 0.001). Hypermagnesemia was associated with AKI (OR = 1.52, 95% CI = 1.27–1.82, p < 0.001), while neither hypermagnesemia nor hypomagnesemia interacted with the AKI stage on the 28-day mortality. Conclusions: Abnormal magnesium levels were associated with 28-day mortality in critically ill children. AKI and hypermagnesemia had a strong association. Graphical abstract: “A higher resolution version of the Graphical abstract is available as Supplementary information”. [Figure not available: see fulltext.]

DOI： 10.1007/s00467-021-05331-1

Web of Science

Scopus

PubMed

Clustering phosphate and iron-related markers and prognosis in dialysis patients 査読有り

Hikaru Morooka, Akihito Tanaka, Daijo Inaguma, Shoichi Maruyama

Clin Kidney J 15 巻 ( 2 ) 頁： 328 - 337 2021年10月

A Case of TAFRO Syndrome with Two Consecutive Renal Biopsies Following the Pathological Course of the Kidney 査読有り

Kato, N; Hasegawa, T; Muto, R; Tanaka, A; Sato, Y; Maeda, K; Furuhashi, K; Saito, S; Kosugi, T; Maruyama, S

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 32 巻 ( 10 ) 頁： 823 - 824 2021年10月

Development of entrustable professional activities for residents rotating nephrology department in a Japanese university hospital: a Delphi study 査読有り

Tanaka A, et al.

BMJ Open 11 巻 ( 8 ) 頁： e047923 2021年8月

Utility of glomerular Gd-IgA1 staining for indistinguishable cases of IgA nephropathy or Alport syndrome. 査読有り

Ishiko S, Tanaka A, Takeda A, Hara M, Hamano N, Koizumi M, Ueno T, Hayashi H, Kondo A, Nagai S, Aoto Y, Sakakibara N, Nagano C, Horinouchi T, Yamamura T, Ninchoji T, Shima Y, Nakanishi K, Yoshikawa N, Iijima K, Nozu K

Clinical and experimental nephrology 25 巻 ( 7 ) 頁： 779 - 787 2021年7月

記述言語：英語出版者・発行元：Clinical and Experimental Nephrology

Background: Pathological findings in Alport syndrome frequently show mesangial proliferation and sometimes incidental IgA deposition, in addition to unique glomerular basement membrane (GBM) changes including thin basement membrane and/or lamellation. However, similar GBM abnormalities are also often observed in IgA nephropathy. Both diseases are also known to show hematuria, proteinuria, and sometimes macrohematuria when associated with viral infection. Therefore, it can be difficult to make a differential diagnosis, even based on clinical and pathological findings. Some recent articles demonstrated that galactose-deficient IgA1 (Gd-IgA1)-specific monoclonal antibody (KM55) could potentially enable incidental IgA deposition to be distinguished from IgA nephropathy. Methods: We performed comprehensive gene screening and glomerular Gd-IgA1 and type IV collagen α5 chain immunostaining for five cases with both IgA deposition and GBM changes to confirm that Gd-IgA1 can help to distinguish these two diseases. Results: Four of the cases were genetically diagnosed with Alport syndrome (Cases 1–4) and one was IgA nephropathy with massive GBM changes, which had a negative gene test result (Case 5). In Cases 1–4, glomerular Gd-IgA1 deposition was not detected, although there was positivity for IgA in the mesangial area. In Case 5, glomerular Gd-IgA1 deposition was observed. Conclusion: Gd-IgA1 expression analysis could clearly differentiate these two disorders. This approach can be applied to identify these two diseases showing identical clinical and pathological findings.

DOI： 10.1007/s10157-021-02054-3

Scopus

PubMed

Relationship between mortality and use of sodium bicarbonate at the time of dialysis initiation: a prospective observational study 査読有り

Morooka Hikaru, Yamamoto Junichiro, Tanaka Akihito, Inaguma Daijo, Maruyama Shoichi

BMC NEPHROLOGY 22 巻 ( 1 ) 頁： 118 2021年4月

記述言語：日本語出版者・発行元：BMC Nephrology

Background: Patients with chronic kidney disease often experience metabolic acidosis. Whether oral sodium bicarbonate can reduce mortality in patients with metabolic acidosis has been debated for years. Hence, this study was conducted to evaluate the utility of sodium bicarbonate in patients who will undergo dialysis therapy. In this study, we investigated the effect of oral sodium bicarbonate therapy on mortality in patients with end-stage kidney disease (ESKD) initiated on dialysis therapy. Methods: We conducted an observational study of patients when they started dialysis therapy. There were 17 centres participating in the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis. Data were available on patients’ sex, age, use of sodium bicarbonate, drug history, medical history, vital data, and laboratory data. We investigated whether patients on oral sodium bicarbonate for more than three months before dialysis initiation had a better prognosis than those without sodium bicarbonate therapy. The primary outcome was defined as all-cause mortality. Results: The study included 1524 patients with chronic kidney disease who initiated dialysis between October 2011 and September 2013. Among them, 1030 were men and 492 women, with a mean age of 67.5 ± 13.1 years. Of these, 677 used sodium bicarbonate and 845 did not; 13.6% of the patients in the former group and 21.2% of those in the latter group died by March 2015 (p < 0.001). Even after adjusting for various factors, the use of sodium bicarbonate independently reduced mortality (p < 0.001). Conclusions: The use of oral sodium bicarbonate at the time of dialysis initiation significantly reduced all-cause mortality in patients undergoing dialysis therapy.

DOI： 10.1186/s12882-021-02330-0

Web of Science

Scopus

PubMed

MAGNESIUM IMBALANCE IS ASSOCIATED WITH 28-DAY MORTALITY IN CRITICALLY ILL CHILDREN: A RETROSPECTIVE OBSERVATIONAL ANALYSIS 査読有り

Hikaru Mrooka, Akihito Tanaka, et al.

Kidney international reports 6 巻 ( 4 ) 頁： S44 - S45 2021年4月

Peripheral artery disease at the time of dialysis initiation and mortality: a prospective observational multicenter study 査読有り

Morooka Hikaru, Tanaka Akihito, Inaguma Daijo, Maruyama Shoichi

BMJ OPEN 10 巻 ( 12 ) 2020年12月

Prognostic Impact of Parameters of Metabolic Acidosis in Critically Ill Children with Acute Kidney Injury: A Retrospective Observational Analysis Using the PIC Database 査読有り

Morooka Hikaru, Kasugai Daisuke, Tanaka Akihito, Ozaki Masayuki, Numaguchi Atsushi, Maruyama Shoichi

DIAGNOSTICS 10 巻 ( 11 ) 2020年11月

記述言語：日本語出版者・発行元：Diagnostics

Acute kidney injury (AKI) is a major complication of sepsis that induces acid-base imbalances. While creatinine levels are the only indicator for assessing the prognosis of AKI, prognostic importance of metabolic acidosis is unknown. We conducted a retrospective observational study by analyzing a large China-based pediatric critical care database from 2010 to 2018. Participants were critically ill children with AKI admitted to intensive care units (ICUs). The study included 1505 children admitted to ICUs with AKI, including 827 males and 678 females. The median age at ICU admission was 22 months (interquartile range 7–65). After a median follow-up of 10.87 days, 4.3% (65 patients) died. After adjusting for confounding factors, hyperlactatemia, low pH, and low bicarbonate levels were independently associated with 28-day mortality (respective odds ratio: 3.06, 2.77, 2.09; p values: <0.01, <0.01, <0.01). The infection had no interaction with the three parameters. The AKI stage negatively interacted with bicarbonate and pH but not lactate. The current study shows that among children with AKI, hyperlactatemia, low pH, and hypobicarbonatemia are associated with 28-day mortality.

DOI： 10.3390/diagnostics10110937

Web of Science

Scopus

PubMed

クロスマッチ陽性生体腎移植の臨床的検討査読有り

藤田高史, 加藤真史, 栃木宏介, 石田昇平, 舟橋康人, 松川宜久, 田中章仁, 齋藤尚二, 安田宣成, 丸山彰一

移植 55 巻 ( 0 ) 頁： 397_1 - 397_1 2020年

記述言語：日本語出版者・発行元：一般社団法人日本移植学会

<p>DSAは抗体関連型拒絶反応のリスク因子であり、①CDC陽性②FCXM陽性③FCXM陰性でDSA陽性の順にDSAの力価が高いと考えられている。クロスマッチ陽性腎移植における脱感作療法後のAMR発生率は12-60％と報告されているが、DSAの力価によりAMRの発生率は異なる。今回われわれは2011年から2019年までに当院で施行された生体腎移植の77例を対象として、FCXM陽性（グループ①、26例）、FCXM陰性でDSA陽性（グループ②、3例）、FCXM陰性（グループ③、48例）に分けて拒絶反応の発生率、CMV抗原血症、生着率について検討した。輸血、妊娠、移植の感作歴はグループ①、②、③でそれぞれ53.8%、33.3%、20.8%、DSAはグループ①に3例、グループ②に3例確認された。脱感作療法としてリツキシマブはグループ①、②、③でそれぞれ65.4%、100%、35.4%に投与されていた。AMRの発生率はグループ①、②、③でそれぞれ15.4%、33.3%、2.1%であった。CMV抗原血症に対してVGCの投与を要した症例はグループ①、②、③でそれぞれ15.3%、33.3%、29.2%であった。3年生着率はグループ①、②、③でそれぞれ100%、100%、92.4%であった。FCXM陽性例およびDSA陽性例はFCXM陰性例に比較するとAMRの発生率は高いが、短期生着率に差は認めなかった。</p>

DOI： 10.11386/jst.55.Supplement_397_1

Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy 査読有り

Therapeutic Apheresis and Dialysis 23 巻 ( 6 ) 頁： 575 - 583 2019年12月

Incidence rate of atrial fibrillation after dialysis initiation and its relationship with cardiovascular events 査読有り

Tanaka A, et al.

Acta Cardiologica 74 巻 ( 6 ) 頁： 527 - 535 2019年11月

Prediction model for cardiovascular events or all-cause mortality in incident dialysis patients 査読有り

Inaguma Daijo, Morii Daichi, Kabata Daijiro, Yoshida Hiroyuki, Tanaka Akihito, Koshi-Ito Eri, Takahashi Kazuo, Hayashi Hiroki, Koide Shigehisa, Tsuboi Naotake, Hasegawa Midori, Shintani Ayumi, Yuzawa Yukio

PLOS ONE 14 巻 ( 8 ) 2019年8月

Efficacy of Long‐Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure 査読有り

Tanaka A, Hiramatsu E, Watanabe Y, Ito C, Shinjo H, Otsuka Y, Takeda A.

Therapeutic Apheresis and Dialysis 2019年8月

Successful treatment of peritoneal dialysis-related peritonitis caused by Dermacoccus nishinomiyaensis 査読有り

Tanaka A, Watanabe Y, Ito C, et al.

CEN Case Reports 2019年8月

Hepatitis B Virus Infection Among Patients With Chronic Kidney Disease Who Attended an Educational Program in Japan 査読有り

Tanaka A, et al.

Therapeutic Apheresis and Dialysis 6 巻頁： 588 - 593 2018年12月

Ratio of blood urea nitrogen to serum creatinine at initiation of dialysis is associated with mortality: A multicenter prospective cohort study 査読有り

Inaguma D., Koide S., Ito E., Takahashi K., Hayashi H., Hasegawa M., Yuzawa Y., Tanaka A., Murata M., Shinjo H., Otsuka Y., Takeda A., Tamai H., Naruse T., Kurata K., Oishi H., Aoyama I., Ogawa H., Kushimoto H., Shimizu H., Yamamoto J., Kurata H., Yamakawa T., Yaomura T., Kasuga H., Ichida S., Maruyama S., Matsuo S., Kato N.

Clinical and Experimental Nephrology 22 巻 ( 2 ) 頁： 353 - 364 2018年4月

出版者・発行元：Clinical and Experimental Nephrology

Background Some studies have shown that the estimated glomerular filtration rate (eGFR) at the time of initiating dialysis was associated with mortality. However, the relationship between ratio of blood urea nitrogen to serum creatinine (BUN/Cr) and mortality is unknown. Methods The study was a multicenter, prospective cohort analysis including 1520 patients. Patients were classified into four quartiles based on the BUN/Cr ratio at the dialysis initiation, with Q1 having the lowest ratio and Q4 the highest. All-cause mortality after initiating dialysis was compared using the log-rank test. All-cause mortality of Q1, Q2, and Q3 was compared with that of Q4 using multivariate Cox proportional hazard regression analysis. Moreover, we compared the renal parameters including BUN/Cr ratio, eGFR, and creatinine clearance for sensitivity and specificity using receiver operative characteristic (ROC) curve. Results Significant differences were observed in all-cause mortality among the four groups (p<0.001). Multivariate analysis revealed that all-cause mortality was significantly higher in Q4 than in Q1 [hazard ratio (HR) = 1.82, 95% confidence interval (CI) 1.24–2.67, p = 0.002]. The increase in BUN/Cr ratio was positively associated with mortality (HR 1.04, 95% CI 1.02–1.06, p = 0.002). The sensitivity and specificity of BUN/Cr ratio for 180, 365, 730, and 1095 days mortality ranged between 0.60–0.72 and 0.59–0.71, respectively. The area under the curve of BUN/Cr for all-cause mortality was the highest among the renal parameters. Conclusion The BUN/Cr ratio at the time of initiation of dialysis was associated with all-cause mortality.

DOI： 10.1007/s10157-017-1458-x

Scopus

Relationship Between Mortality and Cancer-Bearing Status in Patients With Chronic Kidney Disease Who Attended an Educational Program. 査読有り

Tanaka A, Inaguma D, Watanabe Y, Murata M, Shinjo H, Koike K, Otsuka Y, Takeda A

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 22 巻 ( 1 ) 頁： 49 - 57 2018年2月

記述言語：英語出版者・発行元：Therapeutic Apheresis and Dialysis

Patients with malignancy have a poorer prognosis than others do, which must be taken into consideration when treating them for chronic kidney disease (CKD). However, there are few studies investigating their prognosis. This was an observational study of 515 (394 men and 121 women) stable non-dialysis patients with CKD who attended a CKD educational program. Mean age was 68.8 ± 13.0 years. Median follow-up was 968.5 days. Mean creatinine was 3.4 ± 1.6 mg/dL. Of these, 63 had malignancy and 452 did not; 20.6% of the former and 11.9% of the latter group died by the end of the study period (P = 0.0548). Malignancy was not associated with all-cause mortality (HR: 1.3475, 95% CI: 0.7202–2.5214, P = 0.3507) but with malignancy-associated mortality (HR: 3.9477, 95% CI: 1.6348–9.5331, P = 0.0023). Renal replacement therapy was not associated with mortality. Since malignancy greatly affects the prognosis, it must be taken into consideration when treating these patients.

DOI： 10.1111/1744-9987.12598

Scopus

PubMed

Relationship between the Normalized Protein Catabolic Rate and Mortality or Renal Prognosis in Elderly Patients with Chronic Kidney Disease:A Retrospective Analysis 査読有り

Akihito Tanaka, et al.

Therapeutic Research 39 巻 ( 8 ) 頁： 699 - 708 2018年

Evaluation of the Relationship between the Serum Alkaline Phosphatase Level at Dialysis Initiation and All-Cause Mortality: A Multicenter, Prospective Study 査読有り

Akiko Owaki, Daijo Inaguma, Akihito Tanaka, et al.

Nephron Extra 7 巻 ( 3 ) 頁： 78 - 88 2017年11月

Relationship Between Mortality and Cancer-Bearing Status at Time of Dialysis Initiation. 査読有り

Tanaka A, Inaguma D, Shinjo H, Murata M, Takeda A

記述言語：英語出版者・発行元：Therapeutic Apheresis and Dialysis

Patients with malignancy are reported to have poorer prognosis than those without malignancy. When patients with malignancy develop end-stage kidney disease, clinicians must determine treatment with consideration of prognosis. Furthermore, malignancy is sometimes found at time of dialysis initiation. However, prognosis of patients with malignancy at time of dialysis initiation has not been investigated. A total of 1524 patients with chronic kidney disease who initiated dialysis at 17 centers participating in the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis were included. Patients initiated dialysis between October 2011 and September 2013. Mortality rates were compared between patients with and without malignancy. Types of malignancy and respective prognoses also were assessed. The study included 1030 men and 492 women with a mean age of 67.5 ± 13.1 years. Of these, 92 had malignancy and 1430 did not; 45.7% of the former group and 16.0% of the latter group died by March 2015 (P < 0.01). Even after adjusting for various factors, presence of malignancy remained an independent risk factor for mortality (P < 0.01). Patients with performance status (PS) of 0 had significantly lower mortality (P < 0.01). Patients with malignancy at time of dialysis initiation had poor prognosis. Therefore, presence of malignancy should be taken into consideration when patients initiate dialysis. In patients with malignancy, better PS was associated with better prognosis.

DOI： 10.1111/1744-9987.12525

Scopus

PubMed

Factors associated with severity of sleep apnoea syndrome in patients with chronic kidney disease 査読有り

Tanaka A, et al.

Acta Cardiologica 72 巻 ( 4 ) 頁： 440 - 445 2017年8月

Ferrokinetics is associated with the left ventricular mass index in patients with chronic kidney disease 査読有り

Tanaka A, et al.

Acta Cardiologica 72 巻 ( 4 ) 頁： 460 - 466 2017年8月

Relationship between mortality and Geriatric Nutritional Risk Index (GNRI) at the time of dialysis initiation: A prospective multicenter cohort study 査読有り

Tanaka A., Inaguma D., Shinjo H., Murata M., Takeda A.

Renal Replacement Therapy 3 巻 ( 1 ) 2017年7月

担当区分：筆頭著者記述言語：日本語出版者・発行元：Renal Replacement Therapy

Background: The Geriatric Nutritional Risk Index (GNRI) is a nutritional screening method primarily developed for elderly people; it is also reported to be useful for predicting mortality in patients on maintenance dialysis. However, it is unclear whether it is useful at the time of dialysis initiation, which is accompanied by large weight fluctuations and unstable nutritional status. Methods: The study included 1524 patients with chronic kidney disease who commenced dialysis therapy at 17 centers. Patients commenced dialysis between October 2011 and September 2013 and were followed up until March 2015. Results: We analyzed 1489 patients whose GNRI could be calculated and whose prognosis was clear. The mean GNRI was 87.60 (median 87.86). We divided patients based on the median value into a high (H) and low (L) group. The H group included 728 patients (mean GNRI 95.2 ± 4.9, mean age 65.8 ± 13.2 years, 69.3% men), and the L group included 761 patients (mean GNRI 80.3 ± 6.1, mean age 69.1 ± 12.8 years, 66.0% men). Mortality was significantly higher in the L group (L, 22.2% vs. H, 12.6%, P < 0.001). The rates of infection-associated death in the L group was significantly higher (L, 5.5% vs. H, 1.9%, P < 0.001), although no significant difference was observed regarding cardiovascular disease-associated death (L, 7.6% vs. H, 5.2%, P = 0.059) and malignancy-associated death (L, 3.0% vs. H, 3.0%, P = 1.000). Multivariate analysis showed an association between GNRI and all-cause mortality (HR 0.9852, 95%CI 0.9707-0.9999, P = 0.049) and infection-associated death (HR 0.9484, 95%CI 0.9191-0.9786, P < 0.001). Conclusions: GNRI is useful for predicting mortality even at the time of dialysis initiation. Among the causes of death, GNRI was strongly associated with infection-associated death.

DOI： 10.1186/s41100-017-0108-9

Scopus

Physical function at the time of dialysis initiation is associated with subsequent mortality 査読有り

Daijo Inaguma, Akihito Tanaka, Hibiki Shinjo

Clinical and Experimental Nephrology 21 巻 ( 3 ) 頁： 425 - 435 2017年7月

Relationship between mortality and speed of eGFR decline in the 3 months prior to dialysis initiation. 査読有り

Inaguma D, Murata M, Tanaka A, Shinjo H

Clinical and experimental nephrology 21 巻 ( 1 ) 頁： 159 - 168 2017年2月

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab. 査読有り

Tanaka A, Inaguma D, Watanabe Y, Ito E, Kamegai N, Shimogushi H, Shinjo H, Koike K, Otsuka Y, Takeda A

Internal medicine (Tokyo, Japan) 56 巻 ( 12 ) 頁： 1531 - 1535 2017年

Effect of continuous hemodiafiltration using an AN69ST membrane in patients with sepsis 査読有り

Tanaka A, et al.

Renal Replacement Therapy 3 巻頁： 12 2017年

Association between 1,25-dihydroxyvitamin D and left atrial diameter in pre-dialysis chronic kidney disease patients 査読有り

Daijo Inaguma, Hibiki Shinjo, Akihito Tanaka, et al.

Clinical Nephrology 86 巻 ( 11 ) 頁： 229 - 235 2016年11月

Superior Vena Cava Syndrome-like Phenomenon on Vascular Access 査読有り

Tanaka A. et al.

Heart Views 17 巻 ( 4 ) 頁： 164 - 165 2016年10月

Predialysis Vitamin D Receptor Activator Treatment and Cardiovascular Events after Dialysis Initiation: A Multicenter Observational Study 査読有り

Daijo Inaguma, Akihito Tanaka, et al.

Nephron 133 巻 ( 1 ) 頁： 35 - 43 2016年4月

Presence of Atrial Fibrillation at the Time of Dialysis Initiation Is Associated with Mortality and Cardiovascular Events 査読有り

Tanaka A, et al.

Nephron 132 巻 ( 2 ) 頁： 86 - 92 2016年2月

Association between Plaque Score of the Carotid Artery and the Severity of Sleep Apnea Syndrome in Patients with Chronic Kidney Disease 査読有り

Daisuke Hasegawa, Akihito Tanaka, et al.

Cardiorenal Medicine 6 巻 ( 2 ) 頁： 159 - 168 2016年2月

Risk factors for acute kidney injury after initial acute aortic dissection and their effect on long-term mortality 査読有り

Akiko Kato*, Eri Ito, Naoki Kamegai, Minami Mizutani, Hiroya Shimogushi, Akihito Tanaka, et al.

Renal Replacement Therapy 2 巻頁： 53 2016年

Factors associated with early failure of vascular access in acute-phase patients 査読有り

Tanaka A, et al.

Renal Replacement Therapy 2 巻頁： 59 2016年

The efficacy of tolvaptan as a diuretic for chronic kidney disease patients 査読有り

Tanaka A, et al.

Acta cardiologica 70 巻 ( 2 ) 頁： 217 - 223 2015年4月

Calcified amorphous tumor in the left atrium in a patient on long-term peritoneal dialysis 査読有り

Tanaka A, et al.

Internal Medicine 54 巻 ( 5 ) 頁： 481 - 485 2015年

Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency 査読有り

Tetsuhiko Yasuno, Kenji Osafune, Hidetoshi Sakurai, Isao Asaka, Akihito Tanaka, et al.

Biochemical and Biophysical Research Communications 448 巻 ( 2 ) 頁： 175 - 181 2014年3月

Blood monocyte count may be a predictor of vascular access failure in hemodialysis patients 査読有り

Tanaka A, et al.

Therapeutic Apheresis and Dialysis 17 巻 ( 6 ) 頁： 620 - 624 2013年12月

Catheter related septic inferior vena cava thrombosis 査読有り

Tanaka A, et al.

Indian Journal of Nephrology 23 巻 ( 5 ) 頁： 390 2013年9月

Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro 査読有り

Tanaka A, et al.

PLoS One 8 巻 ( 4 ) 頁： e61540 2013年4月

抗体陰性化を確認後にもかかわらず，ヘパリン再投与によりヘパリン起因性血小板減少症（heparin-induced thrombocytopenia：HIT）を再発した1例査読有り

田中章仁ら

日本透析医学会雑誌 2012年3月

Non-occlusive mesenteric ischemia in a hemodialysis patient 査読有り

Tanaka A, et al.

Internal Medicine 50 巻 ( 5 ) 頁： 523 2011年

An autopsy case of intraabdominal hemorrhage in microscopic polyangiitis 査読有り

Yukiko Ito, Akihito Tanaka, et al.

Internal Medicine 50 巻 ( 14 ) 頁： 1501 - 1502 2011年

Temporal artery involvement in microscopic polyangitis 査読有り

Tanaka A, et al.

Internal Medicine 50 巻 ( 9 ) 頁： 1033 - 1037 2011年

MPO-ANCA、抗GBM抗体、抗核抗体陽性のRPGNの経過中にTTPを合併し、血漿交換が有効であった1例査読有り

田中章仁ら

日本アフェレシス学会雑誌 2010年5月

繰り返す脳血管障害を契機に発見され，胸膜炎，ループス腎炎を合併した高齢発症SLEの一例査読有り

田中章仁ら

臨床リウマチ 2010年2月

Successful treatment of severe hypothyroidism enabled a chronic renal failure patient to discontinue hemodialysis 査読有り

Akihito Tanaka, et al.

Therapeutic Research 31 巻 ( 5 ) 頁： 741 - 745 2010年

胸膜炎を唯一の呼吸器合併症としたMPO-ANCA関連腎炎の１例査読有り

田中章仁ら

臨床リウマチ 2009年7月

　前のページ - 次のページ　

<田中 章仁>

論文 - 田中 章仁

<田中　章仁>

論文 - 田中　章仁